The Incretin System and Cardiovascular Risk: Effects of Incretin-Targeted Therapies

Incretins, such as glucagon-like peptide-1 (GLP-1), are gut peptides that stimulate insulin secretion. Incretin-targeted therapeutics for type 2 diabetes include both direct GLP-1 receptor (GLP-1R) agonists and indirect dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the degradation of nati...

Full description

Saved in:
Bibliographic Details
Published inCurrent cardiovascular risk reports Vol. 5; no. 1; pp. 62 - 69
Main Authors Mundil, Dhanwantee, Noyan-Ashraf, M. Hossein, Husain, Mansoor
Format Journal Article
LanguageEnglish
Published New York Current Science Inc 01.02.2011
Springer Nature B.V
Subjects
Blood pressure
Cardiology
Clinical trials
Diabetes
Drug dosages
Enzymes
Glucagon
Heart rate
Hypertension
Insulin
Ischemia
Medicine
Medicine & Public Health
Peptides
Incretins
Dipeptidyl peptidase-4 inhibitor
Cardiovascular disease
Glucagon-like peptide-1
GLP-1 receptor agonist
Diabetes mellitus
Online AccessGet full text

Cover

More Information
Summary:Incretins, such as glucagon-like peptide-1 (GLP-1), are gut peptides that stimulate insulin secretion. Incretin-targeted therapeutics for type 2 diabetes include both direct GLP-1 receptor (GLP-1R) agonists and indirect dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the degradation of native GLP-1. Evidence from basic mechanistic studies in animal models of cardiovascular disease and emerging evidence from pooled analyses of clinical trials suggest beneficial cardiovascular effects of these drugs in addition to their ability to reduce hyperglycemia. This article reviews the actions of incretin-based drugs on blood pressure, vasomotor function, myocardial ischemia, and other cardiovascular risk factors and proposes additional avenues of research.
ISSN:1932-9520
1932-9563
DOI:10.1007/s12170-010-0141-5